Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $595.20 Average PT from Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has received a consensus recommendation of “Hold” from the twelve analysts that are currently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $595.20.

Several equities research analysts have issued reports on MEDP shares. Leerink Partners set a $620.00 price target on Medpace in a research note on Thursday, July 23rd. Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Truist Financial upped their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada increased their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th.

Medpace Price Performance

Shares of Medpace stock opened at $590.89 on Friday. Medpace has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a market cap of $16.49 billion, a PE ratio of 34.64, a PEG ratio of 2.64 and a beta of 1.15. The company has a 50 day simple moving average of $577.04 and a two-hundred day simple moving average of $502.19.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm earned $3.10 EPS. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace will post 17.54 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 650 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the sale, the chief executive officer directly owned 539,894 shares in the company, valued at $334,880,051.38. This represents a 0.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is owned by insiders.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. purchased a new position in shares of Medpace during the second quarter valued at approximately $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in Medpace during the fourth quarter valued at $30,000. Jones Financial Companies Lllp bought a new position in Medpace in the second quarter valued at about $30,000. Finally, Allied Private Wealth LLC bought a new position in Medpace in the second quarter valued at about $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.